Avitriptan (; development code BMS-180048) is an antimigraine drug of the triptan family which was never marketed. It acts as a serotonin 5-HT1B and 5-HT1D receptor agonist. The drug reached phase 3 clinical trials prior to the discontinuation of its development.
Avitriptan (; development code BMS-180048) is an antimigraine drug of the triptan family which was never marketed. It acts as a serotonin 5-HT1B and 5-HT1D receptor agonist. The drug reached phase 3 clinical trials prior to the discontinuation of its development.
==Pharmacology== {| class="wikitable floatleft" style="font-size:small;" |+ |- ! Target !! Affinity (Ki, nM) |- | 5-HT1A || 19 (Ki)646–>10,000 () |- | 5-HT1B || 1.6–21 (Ki)2.1–2.7 () |- | 5-HT1D || 0.78–4.4 (Ki)0.54 () |- | 5-HT1E || 3,550 (Ki)3,020–>10,000 () |- | 5-HT1F || 78–182 (Ki)81–891 () |- | 5-HT2A || 2,340 (Ki)123 () |- | 5-HT2B || 1,150 (Ki)389 () |- | 5-HT2C || (Ki) () |- | 5-HT3 || >1,000 (rat) |- | 5-HT4 || |- | 5-HT5A || |- | 5-HT6 || |- | 5-HT7 || 759 (Ki)4,170 () |- | α1A–α1D || |- | α2A–α2C || |- | β1–β3 || |- | D1–D5 || |- | H1–H4 || |- | M1–M5 || |- | I1, I2 || |- | σ1, σ2 || |- | || |- | || |- | || |- | || |- class="sortbottom" | colspan="2" style="width: 1px; background-color:var(--background-color-notice-subtle,#eaecf0); color:inherit; text-align: center;" | Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs: |}
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).